A pharmaceutical company CEO inherited a company on the hit list: his predecessor was notorious in the industry for acquiring a rare disease pharmaceutical and thereafter increasing the sales price by an extraordinary percentage and had been convicted of fraud.
The new CEO was doing his best to implement business reforms, but the company nonetheless became the subject of a Senate investigation. He was subpoenaed and required to publicly testify. The company was at a tenuous juncture, and the investigation threatened to overwhelm them. When we were brought in, we:
As a result, the final Committee Report offered only limited and modestly favorable comments about our client while suggesting that it appeared to have changed its business practices.